Novel dipeptidyl peptidase-4-inhibiting peptide derived from β-lactoglobulin

J Pharmacol Sci. 2011;117(1):63-6. doi: 10.1254/jphs.11089sc. Epub 2011 Aug 11.

Abstract

Trypsin-treated β-lactoglobulin significantly decreased the glucose level after an oral glucose tolerance test using mice. We performed the present study to identify the active peptide inhibiting dipeptidyl peptidase-4 from trypsin-treated β-lactoglobulin. Trypsin-treated β-lactoglobulin showed a concentration-dependent inhibition for dipeptidyl peptidase-4, with an IC(50) value of 210 µM, although non-treated β-lactoglobulin showed no significant effect in the in vitro assay. The active peptide was isolated from trypsin-treated β-lactoglobulin and identified as the hexapeptide Val-Ala-Gly-Thr-Trp-Tyr (β-lactoglobulin f15-20). This hexapeptide also exhibited a concentration-dependent inhibitory effect and IC(50) value was 174 µM, suggesting that this hexapeptide is almost totally responsible for the DPP-4 inhibitory activity of trypsin-treated β-lactoglobulin.

MeSH terms

  • Dipeptidyl Peptidase 4 / drug effects*
  • Lactoglobulins / chemistry
  • Lactoglobulins / pharmacology*
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*

Substances

  • Lactoglobulins
  • Protease Inhibitors
  • Dipeptidyl Peptidase 4